U.S. FDA approves Roche's lymphoma therapy

[admin]

The U.S. health regulator has approved Roche Holding AG's therapy for treating a type of rare cancer called follicular lymphoma. Follicular lymphoma is a slow-growing type of non-Hodgkin lymphoma, a cancer that starts in body's white blood cells called lymphocytes. The disease often relapses after the initial therapy and typically becomes harder to treat each time it relapses in a patient.